Global Blood Therapeutics Inc $ 47.89 -0.36 (-0.77%)
Volume:
947,570
Avg Vol (1m):
1,175,998
Market Cap $:
2.96 Bil
Enterprise Value $:
2.59 Bil
P/E (TTM):
0.00
P/B:
6.44
Financial Strength | 5/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Cash-To-Debt | 3.35 | ||
Equity-to-Asset | 0.66 | ||
Debt-to-Equity | 0.35 | ||
Debt-to-EBITDA | -0.55 | ||
Piotroski F-Score | 4 | ||
Altman Z-Score | 5.49 | ||
WACC vs ROIC |
Profitability Rank | 1/10 |
Current | Vs Industry | Vs History | |
---|---|---|---|
Operating Margin % | -344.28 | ||
Net Margin % | -332.94 | ||
ROE % | -51.9 | ||
ROA % | -38.3 | ||
ROC (Joel Greenblatt) % | -393.57 | ||
3-Year EBITDA Growth Rate | -24.8 | ||
3-Year EPS without NRI Growth Rate | -22.6 |
Valuation Rank |
Current | Vs Industry | Vs History | |
---|---|---|---|
PB Ratio | 6.44 | ||
PS Ratio | 34.68 | ||
EV-to-EBIT | -8.68 | ||
EV-to-EBITDA | -9.01 | ||
EV-to-Revenue | 30.59 | ||
Current Ratio | 7.63 | ||
Quick Ratio | 7.2 | ||
Days Inventory | 6577.65 | ||
Days Sales Outstanding | 60.95 | ||
Days Payable | 2681.2 |
Dividend & Buy Back |
Current | Vs Industry | Vs History | |
---|---|---|---|
3-Year Average Share Buyback Ratio | -18.3 |
Valuation & Return |
Current | Vs Industry | Vs History | |
---|---|---|---|
Price-to-Tangible-Book | 6.45 | ||
Earnings Yield (Greenblatt) % | -11.54 |